Risk-benefit analysis of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Expert Opinion on Drug Safety

Volumn 2, Issue 1, 2003, Pages 49-58

  Westerhout, Cynthia M ^a   Boersma, Eric ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

abciximab; acute coronary syndromes (ACS); eptifibatide; lamifiban; platelet glycoprotein IIb IIIa inhibition; tirofiban

Indexed keywords

ABCIXIMAB; ACETIC ACID DERIVATIVE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LAMIFIBAN; MONOCLONAL ANTIBODY; PEPTIDE; TIROFIBAN; TYROSINE;

ACUTE DISEASE; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG SCREENING; ECONOMICS; HUMAN; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

ACETATES; ACUTE DISEASE; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; DRUG EVALUATION; GUIDELINES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; INJECTIONS, INTRAVENOUS; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK ASSESSMENT; TREATMENT OUTCOME; TYROSINE;

EID: 0041883702     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.1.49     Document Type: Review

References (24)

1. TOPOL EJ, BYZOVA TV, PLOW EF: Platelet GPIIb-IIIa blockers. Lancet (1999) 353(9148):227-231. (Pubitemid 29088046)
2. KONG DF, CALIFF RM, MILLER DP et al.: Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1998) 98(25):2829-2835. (Pubitemid 29003963)
3. LIBBY P: Coronary artery injury and atherosclerosis and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. Am. J. Cardiol. (2000) 86(8B):3J-8J.
4. WAGNER CL, MASCELLI MA, NEBLOCK DS, WEISMAN HF, COLLER BS, JORDAN RE: Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. Blood (1996) 88(3):907-914. (Pubitemid 26333313)
5. COLLER BS: The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur. Heart J. (1995) 16 (Suppl. L):L11-L15.
6. SCARBOROUGH RM: Development of eptifibatide. Am. Heart J. (1999) 138(6 Pt 1):1093-1104.
7. JORDAN RE, MASCELLI MA: Pharmacological differentiation of GPIIb/IIIa inhibitors. Eur. Heart J. (1999) 1(Suppl. E):E3-E10.
8. SIMOONS ML: Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet (2001) 357(9272):1915-1924. (Pubitemid 32568331)
9. THE CAPTURE INVESTIGATORS: Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet (1997) 349(9063):1429-1435.
10. SCHULMAN SP, GOLDSCHMIDTCLERMONT PJ, TOPOL EJ et al.: Effects of integrilin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation (1996) 94(9):2083-2089. (Pubitemid 26360497)
11. THE PURSUIT TRIAL INVESTIGATORS: Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy. N. Engl. J. Med. (1998) 339(7):436-443.
12. THE PRISM INVESTIGATORS: A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition In Ischemic Syndrome Management (PRISM) Study Investigators. N. Engl. J. Med. (1998) 338(21):1498-1505.
13. THE PRISM-PLUS INVESTIGATORS: Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N. Engl. J. Med. (1998) 338(21):1488-1497.
14. THE PARAGON INVESTIGATORS: International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation (1998) 97(24):2386-2395.
15. THE PARAGON-B INVESTIGATORS: Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation (2002) 105(3):316-321.
16. THEROUX P, KOUZ S, ROY L et al.: Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. The Canadian Lamifiban Study. Circulation (1996) 94(5):899-905. (Pubitemid 26292838)
17. BOERSMA E, HARRINGTON RA, MOLITERNO DJ et al.: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 359(9302):189-198. (Pubitemid 34113814)
18. BHATT DL, TOPOL EJ: Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA (2000) 284(12):1549-1558.
19. LENDERINK T, BOERSMA E, OHMAN EM, ARMSTRONG PW, WALLENTIN LC, SIMOONS ML: Bleeding events with abciximab in acute coronary syndromes without early revascularisation: an analysis of the GUSTO-IV-ACS trial. Eur. Heart J. (2002). Submitted.
20. LINCOFF AM, CALIFF RM, TOPOL EJ: Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J. Am. Coll. Cardiol. (2000) 35(5):1103-1115. (Pubitemid 30206882)
21. HAMM CW, BERTRAND M, BRAUNWALD E: Acute coronary syndrome without ST elevation: implementation of new guidelines. Lancet (2001) 358(9292):1533-1538. (Pubitemid 33055711)
22. BOERSMA E, PIEPER KS, STEYERBERG EW et al.: Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 101(22):2557-2567. (Pubitemid 30350632)
23. ANTMAN EM, COHEN M, BERNINK PJ et al.: The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making. JAMA (2000) 284(7):835-842. (Pubitemid 30643610)
24. RAO AK, PRATT C, BERKE A et al.: Thrombolysis in Myocardial Infarction (TIMI) Trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J. Am. Coll. Cardiol. (1988) 11(1):1-11. (Pubitemid 18029027)